Overview

Fasted Pharmacokinetic and Bioequivalency Study of Fenofibric Acid

Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacokinetic linearity of a single 35 mg fenofibric acid dose and demonstrate the bioequivalence of three 35 mg fenofibric acid tablets (105 mg total single dose) to a single 105 mg fenofibric acid tablet in healthy adult volunteers when each dose is administered under fasted conditions. Safety and tolerability of these regimens will also be evaluated.
Phase:
Phase 1
Details
Lead Sponsor:
Mutual Pharmaceutical Company, Inc.
Treatments:
Fenofibrate
Fenofibric acid